There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > CD40


CD40 Molecule Information

Name:Tumor necrosis factor receptor superfamily member 5
Target Synonym:Tumor necrosis factor receptor superfamily member 5;CDw40;TNFRSF5;CD40;CD40L receptor;CD_antigen=CD40;B-cell surface antigen CD40;Bp50
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:27
Lastest Research Phase:Phase ?

CD40 Protein Product ListCompare or Buy

CD40 Molecule Synonym Name


CD40 Molecule Background

CD40 is also known as TNFRSF5, Bp50, CDW40, MGC9013, TNFRSF5 and p50, is a member of the TNF receptor superfamily which are single transmembrane-spanning glycoproteins, and plays an essential role in mediating a broad variety of immune and inflammatory responses including T cell-dependent immunoglobulin class switching, memory B cell development, and germinal center formation. CD40 is a costimulatory protein found on antigen presenting cells and is required for their activation. The binding of CD154 (CD40L) on TH cells to CD40 activates antigen presenting cells and induces a variety of downstream effects. CD40 contains 4 cysteine-rich repeats in the extracellular domain, and is expressed in B cells, dendritic cells, macrophages, endothelial cells, and several tumor cell lines. The extracellular domain has the cysteinerich repeat regions, which are characteristic for many of the receptors of the TNF superfamily. Interaction of CD40 with its ligand, CD40L, leads to aggregation of CD40 molecules,which in turn interact with cytoplasmic components to initiate signaling pathways. Early studies on the CD40-CD40L system revealed its role in humoral immunity. Defects in CD40 result in hyper-IgM immunodeficiency type 3 (HIGM3), an autosomal recessive disorder characterized by an inability of B cells to undergo isotype switching, as well as an inability to mount an antibody-specific immune response, and a lack of germinal center formation.

CD40 References

CD40 Related Molecule

CD40 Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
ISF-35 Ad-CD154; Ad-ISF35; ISF-35 Phase Ⅱ Memgen LLC Chronic lymphocytic leukemia (CLL), Non-Hodgkin's lymphoma (NHL) Details
MEDI-5083 MEDI-5083,MEDI 5083,MEDI5083 Phase Ⅰ MedImmune, AstraZeneca Solid tumours Details
APX-005M APX-005; APX-005M; EPI-0050,APX005; APX005M; EPI0050 Phase Ⅱ Epitomics, Apexigen Glioma, Non small cell lung cancer (NSCLC), Gastric cancer, Brain cancer, Renal cell carcinoma, Esophagus cancer, Solid tumours, Pancreatic cancer, Melanoma Details
FFP-104 FFP-104 Phase Ⅱ FF Pharma Crohn's disease, Primary biliary cirrhosis (PBC) Details
CDX-1140 CDX-1140 Phase Ⅰ Celldex Solid tumours Details
Bleselumab 4D-11; ASKP-1240 Phase Ⅱ Kyowa Hakko Kogyo, Astellas Transplant rejection Details
NJA-730 NJA-730,NJA730,NJA 730 Phase Ⅰ NapaJen Pharma Graft versus host disease Details
Autologous IL2 and CD40 ligand-expressing tumor cells (Baylor College of Medicine) Phase Ⅰ Baylor College of Medicine Chronic lymphocytic leukemia (CLL) Details
ONCOS-401 ONCOS-401 Preclinical Targovax Solid tumours Details
BMS-986090 BMS-986090; Anti-CD40-dab,BMS986090 Phase Ⅰ Bristol-Myers Squibb Immunological disorders Details
Anti-CD40 ChiLob7/4 (BioNTech) Phase Ⅱ BioNTech Head and neck cancer, Pancreatic cancer Details
Iscalimab CFZ-533; NVP-CFZ533; OM11-62-MF Phase Ⅱ Novartis Myasthenia gravis, Lupus nephritis, Sjoegren's syndrome, Systemic lupus erythematosus, Graves' disease, Rejection of renal transplantation Details
TNX 100 TNX-100 Phase Ⅰ Chiron, Tanox Autoimmune diseases, Transplant rejection, Crohn's disease Details
Mitazalimab ADC-1013; JNJ-7107; JNJ-64457107 Phase Ⅰ Alligator Bioscience, Janssen Solid tumours Details
Lucatumumab CHIR-12.12; HCD-122 Phase Ⅱ Novartis, Xoma Chronic lymphocytic leukemia (CLL), Follicular lymphoma, Multiple myeloma (MM), Lymphoma Details
CD40L-GVAX CD40L-GVAX; GM-CSF/CD40L; GM.CD40L; hCD40L/hGM-CSF Phase Ⅱ University of South Florida, Cellular Biomedicine Group Lung cancer, Melanoma Details
FFP-102 PG-102; 5-D12 Phase Ⅱ PanGenetics, FF Pharma Psoriatic arthritis, Crohn's disease Details
BI-655064 BI-655064 Phase Ⅱ Boehringer Ingelheim, Abbvie Lupus nephritis, Immune thrombocytopenic purpura, Rheumatoid arthritis (RA) Details
Ravagalimab ABBV-323; PR-1629977 Phase Ⅱ Abbvie Ulcerative colitis Details
SEA-CD40 SEA-CD40 Phase Ⅰ Seattle Genetics Solid tumours, Lymphoma Details
Dacetuzumab PRO-64553; RG-3636; SGN-14; SGN-40; hu-S2C6,huS2C6 Phase Ⅱ Seattle Genetics Diffuse large B cell lymphoma Details
Selicrelumab RG-7876; RO-7009789 Phase Ⅰ Roche Solid tumours, Non-Hodgkin's lymphoma (NHL), Pancreatic cancer Details
Teneliximab BMS-224819 Phase Ⅱ Bristol-Myers Squibb Transplant rejection, Rheumatoid arthritis (RA) Details
CP-870893 CP-870893 Phase Ⅰ Pfizer, National Cancer Institute, H. Lee Moffitt Cancer Center and Research Institute Melanoma Details
CD40 ligand (Celldex Therapeutics) Preclinical Amgen, Celldex Viral infections, Solid tumours, Non-Hodgkin's lymphoma (NHL), Immunological disorders, Renal carcinoma, Head and neck cancer, Cancer Details
SHR-1704 SHR-1704 Phase Ⅰ Jiangsu Hengrui Medicine Solid tumours, Haematological disorders Details
AT-1501 AT-1501 Phase Ⅰ ALS Therapy Development Institute, Anelixis Therapeutics Amyotrophic lateral sclerosis (ALS) Details

This web search service is supported by Google Inc.